Selective oestrogen receptor modulation: molecular pharmacology for the millennium.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  European Journal of Cancer

• Publication date

  1999-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0959-8049(99)00297-XPMID 10674006
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Selective Estrogen Receptor Modulators

  2012cited by this paper
• Droloxifene, a new antiestrogen: Its role in metastatic breast cancer

  2004cited by this paper
• “Studies on the estrogen receptor in breast cancer” — 20 years as a target for the treatment and prevention of cancer

  2004cited by this paper
• Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.

  1999cited by this paper
• The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor.

  1999cited by this paper
• Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta.

  1999cited by this paper
• A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex.

  1999cited by this paper
• Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1.

  1999cited by this paper
• Dominant Activity of Activation Function 1 (AF-1) and Differential Stoichiometric Requirements for AF-1 and -2 in the Estrogen Receptor α-β Heterodimeric Complex

  1999cited by this paper
• Estrogen receptor as a target for the prevention of breast cancer.

  1999cited by this paper
• Coexpression of Estrogen Receptor α and β: Poor Prognostic Factors in Human Breast Cancer?

  1999cited by this paper
• Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer?

  1999cited by this paper
• Tamoxifen, raloxifene, and the prevention of breast cancer.

  1999cited by this paper
• Estrogen Receptor β Activates the Human Retinoic Acid Receptorα -1 Promoter in Response to Tamoxifen and Other Estrogen Receptor Antagonists, but Not in Response to Estrogen

  1999cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins.

  1999cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.

  1998cited by this paper
• Designer estrogens.

  1998cited by this paper
• Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1.

  1998cited by this paper
• The Steroid Receptor Coactivator-1 Contains Multiple Receptor Interacting and Activation Domains That Cooperatively Enhance the Activation Function 1 (AF1) and AF2 Domains of Steroid Receptors*

  1998cited by this paper
• Ligand-independent activation of steroid hormone receptors

  1998cited by this paper
• Exploring the role of sex steroids through studies of receptor deficient mice

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors.

  1998cited by this paper
• LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.

  1998cited by this paper
• The nuclear receptor ligand-binding domain: structure and function.

  1998cited by this paper
• The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor.

  1998cited by this paper
• The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.

  1998cited by this paper
• Effects of CP-336,156, a New, Nonsteroidal Estrogen Agonist/Antagonist, on Bone, Serum Cholesterol, Uterus, and Body Composition in Rat Models.

  1998cited by this paper
• Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.

  1998cited by this paper
• Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.

  1998cited by this paper
• Tamoxifen: the herald of a new era of preventive therapeutics.

  1997cited by this paper
• Molecular basis of agonism and antagonism in the oestrogen receptor

  1997cited by this paper
• Effects of raloxifene hydrochloride on the endometrium of postmenopausal women.

  1997cited by this paper
• Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha.

  1997cited by this paper
• (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen.

  1997cited by this paper
• Human Estrogen Receptor β Binds DNA in a Manner Similar to and Dimerizes with Estrogen Receptor α*

  1997cited by this paper
• Re: Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast Cancer

  1997cited by this paper
• Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene.

  1997cited by this paper
• Correction: Raloxifene Response Needs More Than an Element

  1997cited by this paper
• Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

  1997cited by this paper
• Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta.

  1997cited by this paper
• Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.

  1997cited by this paper
• Estrogen Receptors α and β Form Heterodimers on DNA*

  1997cited by this paper
• MCF-7: the first hormone-responsive breast cancer cell line.

  1997cited by this paper
• Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone.

  1997cited by this paper
• Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor.

  1997cited by this paper
• Steroid receptor coactivator-1 is a histone acetyltransferase

  1997cited by this paper
• p300 is a component of an estrogen receptor coactivator complex.

  1996cited by this paper
• Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones.

  1996cited by this paper
• Role of CBP/P300 in nuclear receptor signalling

  1996cited by this paper
• Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation.

  1996cited by this paper
• Nuclear receptor coactivators and corepressors.

  1996cited by this paper
• Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.

  1996cited by this paper
• A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors.

  1996cited by this paper
• Differential ligand‐dependent interactions between the AF‐2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1.

  1996cited by this paper
• TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors.

  1996cited by this paper
• RIP-140 interacts with multiple nuclear receptors by means of two distinct sites

  1996cited by this paper
• ER beta: identification and characterization of a novel human estrogen receptor.

  1996cited by this paper
• Interaction of steroid hormone receptors with the transcription initiation complex.

  1996cited by this paper
• A realistic clinical perspective of tamoxifen and endometrial carcinogenesis.

  1996cited by this paper
• Different Regions in Activation Function-1 of the Human Estrogen Receptor Required for Antiestrogen- and Estradiol-dependent Transcription Activation*

  1996cited by this paper
• Cloning of a novel receptor expressed in rat prostate and ovary.

  1996cited by this paper
• Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and Raloxifene

  1996cited by this paper
• ERβ: Identification and characterization of a novel human estrogen receptor

  1996cited by this paper
• Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.

  1995cited by this paper
• Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.

  1995cited by this paper
• The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists.

  1995cited by this paper
• Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor.

  1995cited by this paper
• Polarity-specific activities of retinoic acid receptors determined by a co-repressor

  1995cited by this paper
• Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor.

  1995cited by this paper
• Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily

  1995cited by this paper
• Characterization of the Amino-terminal Transcriptional Activation Function of the Human Estrogen Receptor in Animal and Yeast Cells (*)

  1995cited by this paper
• Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor

  1995cited by this paper
• Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein

  1995cited by this paper
• Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase

  1995cited by this paper
• Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo.

  1995cited by this paper
• Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens.

  1995cited by this paper
• A transcriptional co-repressor that interacts with nuclear hormone receptors

  1995cited by this paper
• Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens in mammalian cells.

  1994cited by this paper
• Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions.

  1994cited by this paper
• Human TAFII30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor.

  1994cited by this paper
• Interaction of proteins with transcriptionally active estrogen receptors.

  1994cited by this paper
• Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

  1994cited by this paper
• Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription.

  1994cited by this paper
• Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I.

  1993cited by this paper
• Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast.

  1993cited by this paper
• Different TBP-associated factors are required for mediating the stimulation of transcription in vitro by the acidic transactivator GAL- VP16 and the two nonacidic activation functions of the estrogen receptor

  1993cited by this paper
• The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling.

  1993cited by this paper
• Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II).

  1992cited by this paper
• Mechanisms of antihormone action.

  1992cited by this paper
• Year Book of Pathology and Clinical Pathology

  1992cited by this paper
• Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.

  1992cited by this paper
• Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors.

  1992cited by this paper
• Effects of tamoxifen on cardiovascular risk factors in postmenopausal women.

  1991cited by this paper
• Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy.

  1991cited by this paper
• Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient.

  1991cited by this paper
• Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ mice.

  1990cited by this paper
• Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen.

  1990cited by this paper

• In memory of V. Craig Jordan (1947-2024): "Father of tamoxifen" and discoverer of SERMs.

  2024cites this paper
• Glutathione and Xanthine Metabolic Changes in Tamoxifen Resistant Breast Cancer Cell Lines are Mediated by Down-Regulation of GSS and XDH and Correlated to Poor Prognosis

  2024cites this paper
• Two-component symmetrical diarylation of ynamides.

  2023cites this paper
• A syn outer-sphere oxidative addition: the reaction mechanism in Pd/Senphos-catalyzed carboboration of 1,3-enynes

  2023cites this paper
• Synthesis of Multisubstituted Allylic Alcohols via a Nickel-Catalyzed Cross-Electrophile Ring-Opening Reaction.

  2022cites this paper
• Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team

  2021cites this paper
• Rh(III)-Catalyzed Divergent Synthesis of Alkynylated Imidazo[1,5-a]indoles and α,α-Difluoromethylene Tetrasubstituted Alkenes.

  2021cites this paper
• Stereoconvergent and -divergent Synthesis of Tetrasubstituted Alkenes by Nickel-Catalyzed Cross-Couplings.

  2021cites this paper
• Synthesis of Tri-Substituted Olefin Derivatives from 1-Alkene-1,2-Diboronic Esters via Sequential Suzuki-Suzuki Coupling Reaction and Their Biological Activity

  2021cites this paper
• Temperature‐Controlled Divergent Synthesis of Tetrasubstituted Alkenes and Pyrrolo[1,2‐ a ]indole Derivatives via Iridium Catalysis

  2021cites this paper
• Recent advances in the stereoselective synthesis of acyclic all-carbon tetrasubstituted alkenes.

  2021cites this paper
• The ruthenium(ii)-catalyzed C-H olefination of indoles with alkynes: the facile construction of tetrasubstituted alkenes under aqueous conditions.

  2020cites this paper
• Transition-metal mediated carbon-sulfur bond activation and transformations: an update.

  2020cites this paper
• Ligand-free copper-catalyzed regio- and stereoselective 1,1-alkylmonofluoroalkylation of terminal alkynes.

  2020cites this paper
• Rhodium(III)-Catalyzed C-H Alkenylation/Directing Group Migration for the Regio- and Stereoselective Synthesis of Tetrasubstituted Alkenes.

  2020cites this paper
• Cyclopentadienyl cobalt(III) complexes: Synthetic and catalytic chemistry

  2019cites this paper
• Epigenetic Mechanisms of Resveratrol and Its Analogs in Cancer Prevention and Treatment

  2019cites this paper
• Comprehensive RNA sequencing and co-expression network analysis to complete the biosynthetic pathway of coumestrol, a phytoestrogen

  2019cites this paper
• Highly stereoselective nickel-catalyzed difluoroalkylation of aryl ketones to tetrasubstituted monofluoroalkenes and quaternary alkyl difluorides† †Electronic supplementary information (ESI) available. CCDC 1565189 and 1880997. For ESI and crystallographic data in CIF or other electronic format see

  2019cites this paper
• Palladium-Catalyzed Domino Reaction for Stereoselective Synthesis of Multisubstituted Olefins: Construction of Blue Luminogens.

  2018cites this paper
• Iodine-promoted stereoselective amidosulfenylation of electron-deficient alkynes

  2018cites this paper
• A Targeted Bivalent Androgen Receptor Binding Compound for Prostate Cancer Therapy

  2018cites this paper
• Nickel-Catalyzed Directed Hydroarylation of Alkynes with Boronic Acids

  2018cites this paper
• Cesium-catalyzed highly regioselective synthesis of (Z)-vinylic selenosulfides via thioselenation of alkynes with unsymmetrical diorganoyl dichalcogenides

  2017cites this paper
• Highly Stereoselective Synthesis of Tetrasubstituted Acyclic All-Carbon Olefins via Enol Tosylation and Suzuki-Miyaura Coupling.

  2017cites this paper
• Stereo-defined synthesis of differentially all-carbon tetrasubstituted alkenes derived from (E)-1-bromo-2-iodoalkenes

  2017cites this paper
• Photoredox-Catalyzed C-H Arylation of Internal Alkenes to Tetrasubstituted Alkenes: Synthesis of Tamoxifen.

  2017cites this paper
• Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.

  2017cites this paper
• Stereoselective Synthesis of Tetrasubstituted Alkenes via a Cp*CoIII -Catalyzed C-H Alkenylation/Directing Group Migration Sequence.

  2017cites this paper
• Lithium Hexamethyldisilazide-Mediated Enolization of Highly Substituted Aryl Ketones: Structural and Mechanistic Basis of the E/Z Selectivities.

  2017cites this paper
• Cu/Pd-Catalyzed Cascade Reactions of Cyclic Diaryliodoniums and Alkynes - Access to Fluorenes with Conjugate Enynes/Dienes

  2016cites this paper
• Recent progress in transition metal-catalyzed stereoselective synthesis of acyclic all-carbon tetrasubstituted alkenes

  2016cites this paper
• The Dual Estrogen Receptor α Inhibitory Effects of the Tissue-Selective Estrogen Complex for Endometrial and Breast Safety

  2016cites this paper
• Tamoxifen metabolite endoxifen interferes with the polyamine pathway in breast cancer

  2016cites this paper
• Nickel-Catalyzed Regioselective Cleavage of C(sp(2))-S Bonds: Method for the Synthesis of Tri- and Tetrasubstituted Alkenes.

  2016cites this paper
• Selenide-Catalyzed Stereoselective Construction of Tetrasubstituted Trifluoromethylthiolated Alkenes with Alkynes.

  2016cites this paper
• Synthesis of Highly Functionalized Tri- and Tetrasubstituted Alkenes via Pd-Catalyzed 1,2-Hydrovinylation of Terminal 1,3-Dienes

  2015cites this paper
• MOL100925 14..26

  2015cites this paper
• Copper(I)-Catalyzed (Z)-β-(Tosyloxy)alkenyl Iodide Synthesis from (Aryl)[(E)-β-(tosyloxy)alkenyl]iodonium Tosylates: Diversity-Oriented Synthesis of Trisubstituted Alkenes

  2015cites this paper
• Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators.

  2015cites this paper
• Cesium-catalyzed regioselective synthesis of trisubstituted heteroatom alkenes: a new strategy for the preparation of functional alkenes.

  2015cites this paper
• Site-differentiated polyboron arenes prepared by direct C-H borylation and their highly selective Suzuki-Miyaura cross-coupling reactions.

  2014cites this paper
• Tamoxifen as the first successful targeted therapy in cancer: the gift that kept on giving

  2014cites this paper
• Iron-catalyzed tetrasubstituted alkene formation from alkynes and sodium sulfinates.

  2014cites this paper
• Programmed selective sp2 C-O bond activation toward multiarylated benzenes.

  2013cites this paper
• A Synthetic Approach to Tetrasubstituted Alkenes: Using β-Carbonyl Benzothiazol-2-yl Sulfones as Electrophiles

  2013cites this paper
• Structural insights into Resveratrol’s antagonist and partial agonist actions on estrogen receptor alpha

  2013cites this paper
• Receptores de estrógeno e progesterona em pólipos endometriais de usuárias e não usuárias de tamoxifeno e no endométrio atrófico

  2012cites this paper
• The Effect of Selective Estrogen Receptor Modulators (SERMs) on the Tamoxifen Resistant Breast Cancer Cells

  2011cites this paper
• The anti-tumourigenic action of the progesterone receptor antagonist Lonaprisan (ZK230211) in breast cancer

  2011cites this paper
• Hormone und Krebs

  2010cites this paper
• Orphan Nuclear Receptors as Targets for Drug Development

  2010cites this paper
• Reaction behavior of cumulene: Diels-Alder, Friedel-Crafts, and Pd-catalyzed domino reactions

  2010cites this paper
• An Introduction to the Regulation of Sex Steroids for the Treatment of Cancer

  2009cites this paper
• Structure-activity relationships of resveratrol and derivatives in breast cancer cells.

  2009cites this paper
• Methylseleninic acid synergizes with tamoxifen to induce caspase-mediated apoptosis in breast cancer cells

  2008cites this paper
• A novel serine phosphorylation site detected in the n-terminal domain of estrogen receptor isolated from human breast cancer cells

  2008cites this paper
• New steroidal aromatase inhibitors: Suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death

  2008cites this paper
• Insight into estrogen action in breast cancer via the study of a novel nuclear receptor corepressor: SLIRP

  2008cites this paper
• Estrogen directly modulates circadian rhythms of PER2 expression in the uterus.

  2008cites this paper
• Estrogenic activities of isoflavones and flavones and their structure-activity relationships.

  2008cites this paper
• The non-genomic crosstalk between PPAR-γ ligands and ERK1/2 in cancer cell lines

  2007cites this paper
• Estrogenic Activities of Isoflavones and Flavones and their Structure-Activity Relationships

  2007cites this paper
• Stereocontrolled synthesis of tetrasubstituted olefins.

  2007cites this paper
• CANCER DRUG DISCOVERY AND DEVELOPMENT

  2007cites this paper
• Drugs, their targets and the nature and number of drug targets

  2007cites this paper
• Research Article: Quantitative Structure Activity Relationship (QSAR) Study of Estrogen Derivatives Based on Descriptors of Energy and Softness

  2007cites this paper
• Pharmacophore Mapping of Selective Binding Affinity of Estrogen Modulators through Classical and Space Modeling Approaches: Exploration of Bridged-Cyclic Compounds with Diarylethylene Linkage

  2007cites this paper
• Domino Heck-C-H activation reaction of unsymmetrically substituted [3]cumulene.

  2006cites this paper
• Ligand binding by estrogen receptor beta attached to nanospheres measured by fluorescence correlation spectroscopy

  2006influential citation
• Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells

  2006cites this paper
• CD24 expression is specific for tamoxifen-resistant ductal breast cancer cases.

  2006cites this paper
• Multisubstituted olefins: Platform synthesis and applications to materials science and pharmaceutical chemistry

  2006cites this paper
• Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer

  2006cites this paper
• Effects of tamoxifen and glucose on breast cancer T47D cells

  2006cites this paper
• Drugs, their targets and the nature and number of drug targets

  2006cites this paper
• Heteroatom‐Guided Torquoselective Olefination of α‐Oxy and α‐Amino Ketones via Ynolates

  2006cites this paper
• Platform synthesis: A useful strategy for rapid and systematic generation of molecular diversity.

  2006cites this paper
• Resveratrol as a Phytoestrogen

  2005cites this paper
• Sodium nitroprusside-induced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene.

  2005cites this paper
• QSAR of estrogen receptor modulators: exploring selectivity requirements for ER(alpha) versus ER(beta) binding of tetrahydroisoquinoline derivatives using E-state and physicochemical parameters.

  2005cites this paper
• Tamoxifen fails to affect central serotonergic tone but increases indices of anxiety in female rhesus macaques.

  2005cites this paper
• Benign endometrial adenofibroma and polyp in patients receiving tamoxifen: findings on transvaginal ultrasonography and magnetic resonance imaging

  2005cites this paper
• Vitamin D, tamoxifen and β-estradiol modulate breast cancer cell growth and interleukin-6 and metalloproteinase-2 production in three-dimensional co-cultures of tumor cell spheroids with endothelium

  2005cites this paper
• QSAR studies with E-state index: predicting pharmacophore signals for estrogen receptor binding affinity of triphenylacrylonitriles.

  2005cites this paper
• Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.

  2005cites this paper
• Targeting of therapeutic agents to bone to treat metastatic cancer.

  2005cites this paper
• Heteroatom-guided torquoselective olefination of alpha-oxy and alpha-amino ketones via ynolates.

  2005cites this paper
• Selective activation of PPARγ in breast, colon, and lung cancer cell lines

  2005cites this paper
• Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.

  2005cites this paper
• Expression of Cyclin D1 in Tamoxifen Resistant Subline of Human Breast Cancer T47D Cells

  2005cites this paper
• Differential gene expression assessed by cDNA microarray analysis in breast cancer tissue under tamoxifen treatment.

  2005cites this paper
• Role of oestrogen receptor phosphorylation in the growth of endocrine-responsive and anti-oestrogen-resistant breast cancer cell lines

  2005cites this paper
• Interaction of the aryl hydrocarbon receptor ligand 6-methyl-1,3,8-trichlorodibenzofuran with estrogen receptor alpha.

  2004cites this paper
• Stereoselective olefination of unfunctionalized ketones via ynolates.

  2004cites this paper
• Human CYP1B1 is regulated by estradiol via estrogen receptor.

  2004cites this paper
• Reduction of tamoxifen resistance in human breast carcinomas by tamoxifen-containing liposomes in vivo

  2004cites this paper
• The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells.

  2004cites this paper
• Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.

  2004cites this paper
• Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ

  2004cites this paper